RSAD2

Across TCGA pan-cancer cohorts, RSAD2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RSAD2 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher RSAD2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RSAD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, HNSC, and UCEC are the cancer types where RSAD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.514	0.963	<.001	36	view →
HNSC	DFS	Median	All	0.206	0.711	.001	18	view →
UCEC	DFS	Median	II,III,IV	1.000	0.441	.024	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	OS	Median	III,IV	0.126	0.664	.033	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RSAD2–BRCA (OS)

Open the BRCA breakdown →